Shao-An Xue

Title: The Innovative Contributions of Shao-An Xue

Introduction

Shao-An Xue is a prominent inventor based in London, GB. He has made significant contributions to the field of therapeutically useful molecules, particularly in the development of T cell receptor (TCR) molecules. With a total of six patents to his name, Xue's work is at the forefront of medical innovation.

Latest Patents

One of Shao-An Xue's latest patents focuses on a T cell receptor molecule that contains both an alpha chain portion and a beta chain portion. The alpha chain portion includes three complementarity determining regions (CDRs): CDR1α: SSYSPS, CDR2α: YTSAATL, and CDR3α: VVSPFSGGGADGLT or comprising or consisting of SPPSGGGADGLT. The beta chain portion also contains three CDRs: CDR1β: DFQATT, CDR2β: SNEGSKA, and CDR3β: comprising SARDGGEG or comprising or consisting of RDGGEGSETQY. This invention also encompasses polynucleotides encoding the TCR molecules and host cells containing these polynucleotides. Patient-derived T cells may have the polynucleotides introduced, allowing engineered T cells to be used in combating WT1-expressing malignancies.

Career Highlights

Throughout his career, Shao-An Xue has worked with notable companies such as Imperial Innovations Limited and UCL Business Plc. His work in these organizations has contributed to advancements in biotechnology and therapeutic development.

Collaborations

Shao-An Xue has collaborated with esteemed colleagues, including Hans Josef Stauss and Liquan Gao. These partnerships have further enhanced his research and innovation in the field.

Conclusion

Shao-An Xue's contributions to the field of therapeutically useful molecules and T cell receptor technology highlight his role as a leading inventor. His innovative work continues to pave the way for advancements in medical treatments and therapies.